




# A biologic strategy built to save



As costs for complex biologic specialty medications continue to soar, biosimilars create a more competitive marketplace that supports improved affordability for clients and members. UnitedHealthcare provides coverage for biosimilars when it makes sense, to help ensure a robust pipeline of future products.

Let's look at how biologic innovators and biosimilars are different from conventional branded and generic medications.

## They are made differently

Biologics and biosimilars are made from living cells.



### Brand and generic medications

Aspirin (acetylsalicylic acid)



small molecule, easy to make



### Biologic and biosimilar medications

Biologically engineered antibody



large molecule, difficult to make

## They are produced differently



Conventional drugs can be simply mass-produced



Biologics and biosimilars require sophisticated production processes and are more difficult to manufacture

## They are expensive to produce

Biologics contain the same active ingredient as innovator biologic medications but are still as expensive to produce. So they don't drive savings the way generics do—they compete like brand medications.



Original biologic medications



Biosimilar medications

## Management strategies

At UnitedHealthcare, we offer management strategies designed to support member health at the lowest net cost. Each innovator (original biologic) and its biosimilars are evaluated one by one, and we make coverage decisions based on cost and other factors.

Drug	Category	Innovator brand(s)	Biosimilar brand(s) <sup>1</sup>	Administration method	Preferred product <sup>2</sup>
Filgrastim	Cancer support	Granix® Neupogen®	Nivestym® Releuko® Zarxio®	Physician administered or self-injected	<b>Zarxio</b> Preferred product for both the pharmacy and medical benefits
Pegfilgrastim	Cancer support	Neulasta®	Fulphila® Fynetra® Nlyvepria™ Stimufend® Udenyca® Ziextenzo®	Physician administered or self-injected	<b>Neulasta</b> <b>Ziextenzo</b> Preferred products for both the pharmacy and medical benefits
Infliximab	Inflammatory conditions	Remicade®	Avsola™ Inflectra® Renflexis®	Physician administered	<b>Avsola</b> <b>Inflectra</b> Preferred products for the medical benefit
Epoetin alfa	Anemia	Epogen® Procrit®	Retacrit®	Physician administered or self-injected	<b>Retacrit</b> Preferred product for both the pharmacy and medical benefits
Bevacizumab	Cancer	Avastin®	Almsys® Mvasi™ Zirabev®	Physician administered	<b>Mvasi</b> Preferred product for the medical benefit
Trastuzumab	Cancer	Herceptin®	Herzuma® Kanjinti® Ogivri® Ontruzant® Trazimera™	Physician administered	<b>Kanjinti</b> <b>Trazimera</b> Preferred products for the medical benefit
Rituximab	Cancer	Rituxan®	Ruxience® Truxima® Riabni™	Physician administered	<b>Ruxience</b> <b>Truxima</b> Preferred products for the medical benefit
Semglee	Diabetes	Lantus®	Rezvoglar Semglee insulin glargine-yfgn	Self-injected	<b>Lantus</b> Preferred product for the pharmacy benefit
Ranibizumab	Retinal disorders	Lucentis®	Byooviz® <sup>3</sup> Cimerli®	Physician administered	<b>Lucentis</b> <b>Cimerli</b> Preferred products for the medical benefit
Adalimumab	Inflammatory conditions	Humira®	Abrilada™ Amjevita™ Cyltezo® Hadlima™ Hyrimoz® Hulio® Idacio® Yuflyma® Yusimry™	Self-injected	<b>Humira</b> <b>Amjevita</b> <b>Cyltezo</b> <b>Hadlima</b> <b>adalimumab-ada</b> (unbranded Hyrimoz) Covered products for the pharmacy benefit



# 53%

medical benefit drug savings with biosimilar management strategies<sup>4</sup>

Contact your UnitedHealthcare representative to learn more about management strategies for biosimilars



<sup>1</sup> Though other biosimilars have been approved by the Food and Drug Administration, those listed here are the only ones that have been launched in the market. We will develop management strategies as more biosimilars launch.  
<sup>2</sup> UnitedHealthcare uses utilization management strategies or exclusions to ongoing products.  
<sup>3</sup> Drug is on UnitedHealthcare Review at Launch list and evaluation is ongoing.  
<sup>4</sup> UnitedHealthcare 2022 commercial book of business data. Savings apply to medical benefit drugs. Savings may vary.  
OptumRx is a subsidiary of UnitedHealth Group. UnitedHealthcare and the dimensional U logo are trademarks of UnitedHealth Group Incorporated. All other trademarks are the property of their respective owners.  
B2B 12/23 ©2023 United HealthCare Services, Inc. All rights reserved. WF12501587\_231215